Skip to main content

Advertisement

Table 3 Demographic and clinical characteristics at baseline

From: Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study

  G1m phenotype
  3,3 3,17 17,17
  n = 120 n = 98 n = 32
Demographics    
Age, years 53 ± 14 53 ± 12* 48 ± 12*
Female, no. (%) 95 (79) 74 (76) 28 (88)
DMARD therapy    
Prior DMARDs (no.) 3.5 ± 1.6 3.4 ± 1.7 3.3 ± 1.6
Methotrexate use, no. (%) 95 (79) 81 (83) 23 (72)
Methotrexate dose (mg/wk) 21 (15 to 25) 25 (15 to 25) 25 (17.5 to 25)
Prednisone use, no. (%) 39 (33) 31 (32) 12 (38)
Prednisone dose (mg/day) 7.5 (5 to 10) 5 (5 to 7.5) 10 (5 to 10)
Disease status    
Disease duration (years) 10 (4 to 17) 11 (3 to 16) 7 (3 to 17)
Rheumatoid factor positive, no. (%) 80 (67)* 70 (71) 29 (91)*
Erosive disease, no. (%) 90 (75) 76 (78) 28 (88)
Erythrocyte sedimentation rate (mm/h) 29 ± 23 31 ± 25 28 ± 17
C-reactive protein (mg/dl) 11 (4 to 24) 10 (6 to 23) 14 (6 to 31)
DAS28 5.1 ± 1.2 5.3 ± 1.2 5.2 ± 1.0
  1. DAS28, Disease Activity Score in 28 joints; DMARD, diseases modifying anti rheumatic drug.
  2. *There was a significant difference between patients with the 3,17-allotype and the 17,17-allotype for age (P = 0.020), and between both homozygous groups 3,3 and 17,17 for rheumatoid factor positivity, no. (P = 0.007).